Madrigal Pharma: Inside the MAESTRO-NASH Breakthrough- How Weight Loss Supercharges Antifibrotic Effects!

Madrigal Pharmaceuticals, a company focused on the treatment of nonalcoholic steatohepatitis (NASH), shared significant progress during its third-quarter 2025 results. The primary highlight was the robust performance of its lead product Rezdiffra, which is garnering noteworthy sales traction. Rezdiffra has quickly climbed the ladder in the specialty pharmaceutical market with annualized revenues surpassing $1 billion, achieved in just six quarters post-launch. This growth is driven by the adoption from over 29,500 patients and prescriptions by more than 10,000 healthcare providers.